ArticleNature medicine2019
Small-molecule targeting of brachyury transcription factor addiction in chordoma.
Abstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 1 pooled it
19.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 1 synthesis or guideline pooled it, 163 citations in OpenAlex.
- Pooled it
- Apparent diffusion coefficient as a prognostic factor in clival chordoma.Scientific reports · 2021Trial
- Ultrastructural pathological features and clinical significance of recurrent chordoma.Journal of bone oncology · 2026Article
- Targeting chordoma via an isocitrate dehydrogenase-1-dependent susceptibility to redox metabolism.Acta neuropathologica · 2026Article
- The notochord: development, disease and stem cell-based modelling.Development (Cambridge, England) · 2026Review
- Immune infiltration is associated with distinct transcriptional states and metabolic profiles in chordomas.iScience · 2026Article
- ATF4-mediated stress response as a therapeutic vulnerability in chordoma.Molecular oncology · 2026Article
- Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence.The Journal of clinical investigation · 2026Article
- AI-assisted identification of innovative phytochemicals from Aizoon canariense aimed at brachyury protein in chordoma: a computational strategy.Scientific reports · 2025Article
- Human eosinophils exert antitumorigenic effects on chordoma.Chinese neurosurgical journal · 2025Article
- Phosphorylation of a conserved TBXT threonine residue is vital to vertebral development.Science China. Life sciences · 2025Article
- Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma.Science advances · 2025Article
- The TBXT rs2305089 SNP links the benign notochordal cell tumour and chordoma.The Journal of pathology · 2025Article
- RAB3B Dictates mTORC1/S6 Signaling in Chordoma and Predicts Response to mTORC1-Targeted Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cucurbitacin B Exhibits Antitumor Effects on Chordoma Cells via Disruption of Brachyury.International journal of molecular sciences · 2025Article
- Combinatorial therapies for epigenetic, immunotherapeutic, and genetic targeting of chordoma.Journal of neuro-oncology · 2025Review
- Chromatin Interaction and Histone Mark Signatures Associated With TBXT Expression in Metastatic Lung Cancer.Genes, chromosomes & cancer · 2025Article
- Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy.Nature communications · 2025Article
- The present and future of the Cancer Dependency Map.Nature reviews. Cancer · 2025Review
- Super-Enhancer Reprograming Driven by SOX9 and TCF7L2 Represents Transcription-Targeted Therapeutic Vulnerability for Treating Gallbladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 10 institutions in 4 countries.
Tanaz SharifniaBroad Institute of Harvard and MIT, Cambridge, MA, USA. tanaz@broadinstitute.org.ORCID http://orcid.org/0000-0001-7274-164X
Mathias J WawerBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Ting ChenNew York University Langone Medical Center, New York, NY, USA.
Qing-Yuan HuangNew York University Langone Medical Center, New York, NY, USA.
Barbara A WeirBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Ann SizemoreBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Matthew A LawlorDana-Farber Cancer Institute, Boston, MA, USA.
Amy GoodaleBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Glenn S CowleyBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0526-0616
Francisca VazquezBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2857-4685
Christopher J OttDana-Farber Cancer Institute, Boston, MA, USA.
Joshua M FrancisBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Slim SassiMassachusetts General Hospital, Boston, MA, USA.
Patricia CogswellChordoma Foundation, Durham, NC, USA.
Hadley E SheppardBaylor College of Medicine, Houston, TX, USA.
Tinghu ZhangDana-Farber Cancer Institute, Boston, MA, USA.
Nathanael S GrayDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5354-7403
Paul A ClarkeCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-9342-1290
Julian BlaggCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.
Paul WorkmanCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.
Josh SommerChordoma Foundation, Durham, NC, USA.
Francis HornicekMassachusetts General Hospital, Boston, MA, USA.
David E RootBroad Institute of Harvard and MIT, Cambridge, MA, USA.
William C HahnBroad Institute of Harvard and MIT, Cambridge, MA, USA.
James E BradnerDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2718-4415
Kwok K WongNew York University Langone Medical Center, New York, NY, USA.
Paul A ClemonsBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Charles Y LinBaylor College of Medicine, Houston, TX, USA. Charles.Y.Lin@bcm.edu.ORCID http://orcid.org/0000-0002-9155-090X
Joanne D KotzBroad Institute of Harvard and MIT, Cambridge, MA, USA. jkotz@jnanatx.com.ORCID http://orcid.org/0000-0002-1915-1605
Stuart L SchreiberBroad Institute of Harvard and MIT, Cambridge, MA, USA. stuart_schreiber@harvard.edu.ORCID http://orcid.org/0000-0003-1922-7558
Broad Institute · USDana-Farber Cancer Institute · USInstitute of Cancer Research · GBBaylor College of Medicine · USChordoma Foundation · USMassachusetts General Hospital · USNYU Langone Health · USHarvard University · USShanghai Jiao Tong University · CNUCLA Medical Center · US
Funding
The Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8MPROGRAM IN HUMAN MOLECULAR GENETICST32GM008307 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI SHAULSKY, GAD · 1990 to 2020
$6.6MTargeting vulnerabilities of therapy-resistant cancer cell states with small moleculesU01CA217848 · NCI · BROAD INSTITUTE, INC. · PI SCHREIBER, STUART L · 2017 to 2021
$5.8MCancer dependencies associated with genomic alterations and targeted by small molU01CA176152 · NCI · BROAD INSTITUTE, INC. · PI SCHREIBER, STUART L · 2013 to 2016
$4.4MIdentifying and Targeting Onocgenic MYC Enhancer Control in Pediatric TumorsR01CA215452 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WESTBROOK, THOMAS · 2017 to 2021
$2.0MChemical Modulation of Chromatin Signaling in Lymphoid MalignanciesR00CA190861 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI OTT, CHRISTOPHER J · 2017 to 2019
$737kCancer Research UK 22897NCI NIH HHS R00 CA190861NCI NIH HHS R01 CA215452NCI NIH HHS U01 CA176058NCI NIH HHS U01 CA176152NCI NIH HHS U01 CA217848NIGMS NIH HHS T32 GM008307
Abstract
Chordoma is a primary bone cancer with no approved therapy
Indexed as
Brachyury ProteinCell ProliferationChordomaCyclin-Dependent KinasesDown-RegulationFetal ProteinsGenes, EssentialHumansProtein Kinase InhibitorsSmall Molecule LibrariesT-Box Domain ProteinsTranscription FactorsBrachyury ProteinCyclin-Dependent KinasesFetal ProteinsProtein Kinase InhibitorsSmall Molecule LibrariesT-Box Domain ProteinsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.